3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
295
Carcinoma, Non-Small-Cell Lung
160
Lung Neoplasms
89
Breast Neoplasms
84
Urinary Bladder Neoplasms
83
Cholangiocarcinoma
58
Neoplasms
53
Neoplasm Metastasis
51
Ovarian Neoplasms
45
Biliary Tract Neoplasms
45
Lymphoma, Large B-Cell, Diffuse
32
Lymphoma
30
Sarcoma
29
Hodgkin Disease
28
Recurrence
26
Nasopharyngeal Carcinoma
26
Gallbladder Neoplasms
26
Carcinoma, Transitional Cell
26
Adenocarcinoma
22
Triple Negative Breast Neoplasms
20
Fallopian Tube Neoplasms
20
Bile Duct Neoplasms
20
Adenocarcinoma of Lung
20
Carcinoma, Renal Cell
17
Carcinoma, Ovarian Epithelial
16
Urethral Neoplasms
15
Lymphoma, Non-Hodgkin
15
Colorectal Neoplasms
14
Leiomyosarcoma
13
Kidney Neoplasms
13
Interventions
vandetanib
2
Cisplatin
2
dalotuzumab
1
X-Rays
1
Tissue Plasminogen Activator
1
Receptors, Vascular Endothelial Growth Factor
1
Pemetrexed
1
Octreotide
1
Naproxen
1
Gemcitabine
1
Cdc25C phosphatase (211-221)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pleural Effusion
×
Gemcitabine
×
Clear all
NCT00753714
2016-10-17
ZELIG
Sanofi
Phase 2
Completed
124 enrolled
11 charts